Humacyte up on positive trial data for bio-engineered human tissue

Humacyte

17/11/2023 19:10

** Shares of Humacyte  HUMA.O  rise 3.7% to $2.53 in
afternoon trade
    ** Co says its implantable, bio-engineered human tissue was
found more effective in a mid- to late-stage trial at 
maintaining blood flow in people with serious injuries in
arteries, when compared with synthetic grafts 
    ** Number of patients who needed amputation procedures in
extreme cases were more than halved, compared with synthetic
grafts
    ** Infection rates were also less than half for the tissue
or Human Acellular Vessel (HAV) vs synthetic graft
    ** U.S. FDA advised co to include data from another study it
conducted in Ukraine in people injured in the war for HAV's
authorization submission
    ** HAV was found to be more effective than synthetic grafts
in the second study in Ukraine as well and co recorded no
amputations
    ** Five of 6 brokerages rate the stock "buy" or higher, 1
"hold"; their median PT is $5 - LSEG
    ** Including session's gain, stock up 19% YTD vs a 10.2%
decline in the Nasdaq Biotechnology Index  .NBI 

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))